Ensuring value, access & uptake of innovative medicines & vaccines, now & in the future

Meeting takes place in a large room, with many seated delegates round the table, with the closest gesturesg while he makes his point
Single National Formulary 2026 768X432

ABPI position on the government’s plans to develop a Single National Formulary in England

The ABPI welcomes the government’s intentions to accelerate equitable adoption of innovative medicines in line with the guidance produced by NICE. Overcoming long-standing barriers to adoption of new medicines that are clinically and cost effective is essential for improving equity of access and patient and NHS outcomes. 

Read more
Cancer Infographic 2026 768X432

Improving access to cancer medicines

Access to innovative cancer medicines transforms lives – helping patients live longer, healthier lives, supporting earlier recovery, and easing pressure on the NHS. By improving how these treatments are valued, funded, and adopted across the health system, we can deliver faster access for patients, better outcomes for families, and a stronger, more resilient life sciences sector that drives the UK’s global leadership in cancer innovation.

Download the infographic: Improving access to cancer medicines
Transforming lives, raising productivity

title-strip icon Transforming lives, raising productivity

A new report from PwC for the ABPI shows that, while the NHS has made progress in recent years, access to medicines in the UK remains poor especially in comparison to other developed countries.

Woman at a meeting, sits smiling at the unseen delegates

title-strip icon UK medicine pricing

Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.

 NICE Methods Review spread open

title-strip icon NICE methods and process evolution

NICE continues to evolve its methods and processes for evaluating new medicines. Making changes that support patient access remains a priority for the ABPI.

 Advanced Therapy Medicinal Products (ATMPs)

title-strip icon Advanced Therapy Medicinal Products (ATMPs)

Advanced Therapy Medicinal Products (ATMPs) are recognised for their potential to revolutionise the way diseases are treated and to transform patient outcomes.

Patient access to combination therapies

title-strip icon Patient access to combination therapies

A combination therapy combines two or more individual medicines (components) into a single treatment regimen.

 Appropriate prescribing document spread open

title-strip icon Appropriate prescribing

Prescription medicines are important therapeutic options which can be prescribed in order to prevent, treat or cure diseases and symptoms.

 Healthcare professional about to inject into the shoulder of a patient

title-strip icon Vaccines

Every year, 2 – 3 million lives are saved across the world because of immunisation and only clean water rivals vaccines at reducing infectious diseases and deaths.

Clinical homecare

title-strip icon Clinical homecare

Meeting the healthcare challenges of today and tomorrow requires innovative solutions that shift healthcare into the community.

Medicine supply

Managing medicine shortages

title-strip icon Managing medicine shortages

Every day millions of patients rely on medicines supplied by the pharmaceutical industry.

 Close up of clear glass medicines bottles moving through a production line in a factory

title-strip icon Counterfeiting

The manufacture and selling of counterfeit medicines is an issue of increasing concern throughout the world. There are potentially fatal consequences for those who inadvertently take such products.